Cargando…

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency

Growth hormone deficiency (GHD) syndrome is associated with adverse levels of several risk factors for cardiovascular diseases (CVD), including metabolic inflammation. However, the impact of GHD and GH treatment on low-grade inflammation is unknown. The aim of the study was to establish the level of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Höybye, Charlotte, Faseh, Laia, Himonakos, Christos, Pielak, Tomasz, Eugen-Olsen, Jesper
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547304/ https://www.ncbi.nlm.nih.gov/pubmed/31151091 http://dx.doi.org/10.1530/EC-19-0159

Ejemplares similares

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
por: Rasmussen, Line Jee Hartmann, et al.
Publicado: (2021)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022)

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
por: Rovina, Nikoletta, et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
por: Özdirik, Burcin, et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases
por: Manfredi, Mariangela, et al.
Publicado: (2023)

Increased Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in Plasma of Suicide Attempters
por: Ventorp, Filip, et al.
Publicado: (2015)

Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy
por: Schultz, Martin, et al.
Publicado: (2019)

The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders
por: Vasarhelyi, Barna, et al.
Publicado: (2016)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients
por: Torino, Claudia, et al.
Publicado: (2018)

Evaluation of soluble urokinase-type plasminogen activator receptor (suPAR) quick test for triage in the emergency department
por: Kumar, Pratyush, et al.
Publicado: (2019)

Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis
por: Vassiliou, Alice G., et al.
Publicado: (2022)

Relationship Between Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Disease Outcome in Adult-Onset Asthma
por: Niemelä, Taito, et al.
Publicado: (2022)

Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience
por: Infantino, Maria, et al.
Publicado: (2022)

suPAR: The Molecular Crystal Ball
por: Thunø, Maria, et al.
Publicado: (2009)

Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study
por: Rasmussen, Line Jee Hartmann, et al.
Publicado: (2016)

Relationship of Circulating Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels to Disease Control in Asthma and Asthmatic Pregnancy
por: Ivancsó, István, et al.
Publicado: (2013)

Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
por: Lee, Jiwon M., et al.
Publicado: (2019)

Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
por: Emrah, Acar, et al.
Publicado: (2016)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19
por: Enocsson, Helena, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Emergency Department (Ed): A Tool for the Assessment of Elderly Patients
por: Holstein, Ria M., et al.
Publicado: (2022)

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Biomarker Associated with Left Ventricular Hypertrophy in the Elderly, Specifically in Women
por: Wlazeł, Rafał Nikodem, et al.
Publicado: (2023)

Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study*
por: Rasmussen, Line J. H., et al.
Publicado: (2018)

Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases
por: Loosen, Sven H., et al.
Publicado: (2018)

The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine
por: Scharrenberg, Jan Simon, et al.
Publicado: (2019)

Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study
por: Schulz, Christina-Alexandra, et al.
Publicado: (2016)

Sex Differences in Circulating Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease
por: Mehta, Anurag, et al.
Publicado: (2020)

Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method
por: Winnicki, Wolfgang, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit
por: Reisinger, Alexander C., et al.
Publicado: (2021)

Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients
por: Jehn, Ulrich, et al.
Publicado: (2021)

Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma
por: Kotsiou, Ourania S., et al.
Publicado: (2022)

High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma
por: Loosen, Sven H, et al.
Publicado: (2019)

The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Context of Aneurysmal Subarachnoid Hemorrhage (aSAH)—A Prospective Observational Study
por: Schmidt, Tobias P., et al.
Publicado: (2022)

Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV‐1‐infected patients: a nested case‐control study
por: Rasmussen, LJH, et al.
Publicado: (2015)

Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus
por: Guthoff, Martina, et al.
Publicado: (2017)

The Relationship Between Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Treatment Response in Patients With Glomerulonephritis: A Single-Center Experience
por: İşsever, Kubilay, et al.
Publicado: (2023)

SuPAR - A future prognostic biomarker in emergency medicine
por: Østervig, Rebecca M, et al.
Publicado: (2015)

Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa
por: Lawn, Stephen D, et al.
Publicado: (2007)

Point-of-care prognostication in moderate Covid-19: Analytical validation and prognostic accuracy of a soluble urokinase plasminogen activator receptor (suPAR) rapid test
por: Chandna, Arjun, et al.
Publicado: (2023)

Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: protocol for a systematic review and meta-analysis
por: Petersen, Jens Emil Vang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qt4eqa090h80bp146ov9mod4l8